Nutra Pharma Corp.
NPHC · OTC
12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | 348.4% | 88.3% | -50.3% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 56.8% | 8.7% | 28.7% | 33.3% |
| R&D Expenses | $0 | $0 | $0 | $0 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $2 | $2 | $1 | $1 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $2 | $2 | $1 | $1 |
| Operating Income | -$2 | -$2 | -$1 | -$1 |
| % Margin | -435.2% | -1,964.6% | -1,782.3% | -1,118.9% |
| Other Income/Exp. Net | $10 | -$11 | $0 | -$5 |
| Pre-Tax Income | $8 | -$13 | -$1 | -$7 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | $8 | -$13 | -$1 | -$7 |
| % Margin | 1,865.7% | -13,399% | -1,482.1% | -6,314.1% |
| EPS | 0.001 | -0.002 | -0 | -0.001 |
| % Growth | 161.1% | -1,700% | 92.9% | – |
| EPS Diluted | 0 | -0.002 | -0 | -0 |
| Weighted Avg Shares Out | 20,442 | 7,233 | 6,607 | 4,710 |
| Weighted Avg Shares Out Dil | 19,097 | 7,233 | 6,607 | 4,710 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $1 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | -$5 |
| EBITDA | -$2 | -$13 | -$0 | -$6 |
| % Margin | -430% | -12,827% | -704.6% | -5,988.9% |